Abbott profits plumment after AbbVie spinoff; Mylan prevails in one Copaxone patent battle;

@FiercePharma: More tit-for-tat in Vivus proxy fight: FMC sues over meeting delay. $VVUS didn't like scoreboard, says Colin. Story | Follow @FiercePharma

 @EricPFierce: FDA says Cispharma didn't do enough to make sure blood tissue didn't get into drugs when worker injured. Article | Follow @EricPFierce

 @CarlyHFierce: NICE nixes Pfizer's CML drug Bosulif. Article | Follow @CarlyHFierce

> Abbott Laboratories ($ABT) posted a 72% drop in profits for the second quarter, partially because of the spinoff of its AbbVie ($ABBV) pharmaceuticals business in January. Report

> In the long-running fight over Teva Pharmaceutical Industries' ($TEVA) patent on its top-selling Copaxone drug, a U.S. judge tossed out infringement claims against Mylan ($MYL), partially clearing the way for generics. Report

> GlaxoSmithKline ($GSK) CEO Andrew Witty will step down as lead independent director on a U.K. government board at the end of his term, the company said, adding that the move is unrelated to bribery allegations GSK faces in China. Report

> Indian drugmakers Cipla and Alembic reportedly are challenging the government's new drug-price controls, citing provisions requiring companies to pull existing stocks within 45 days. Report

> The FDA said the manufacturer of two popular sports supplements, Dallas-based USPlabs, volutarily destroyed its stock of the products. Report

Medical Device News

@FierceMedDev: Popular yesterday: For J&J, no device growth without Synthes. Article | Follow @FierceMedDev

 @MarkHFierce: The device tax has already cost the industry $1 billion. Editor's corner | Follow @MarkHFierce

@DamianFierce: Will all that M&A help Abbott turn its medical device sales around? More | Follow @DamianFierce

> St. Jude's Q2 produces mixed results, but CEO asserts progress. Story

> Abbott's device sales sag, but M&A could brighten the future. More

> Medical device ID plan faces delays. Item

Biotech News

@FierceBiotech: Popular: Is this the NIH Francis Collins wanted to create? Editor's corner | Follow @FierceBiotech

 @JohnCFierce: GSK China official: We inflated conference costs, handed out bribes, pocketed cash and upped drug prices. More | Follow @JohnCFierce

@RyanMFierce: Bioinformatics buy bolsters Life's diagnostics pact with Merck Serono. Report | Follow @RyanMFierce

 @EmilyMFierce: Animal studies produce many false positives. More | Follow @EmilyMFierce

> Buzz: Pfizer prowls Onyx auction block as bidding looms. Report

> Sequella scouts $38M round after nabbing Pfizer antibiotic. Article

> Lundbeck, Otsuka tout improved cognition in mid-stage Alzheimer's study. More

Drug Delivery News

 @MichaelGFierce: Rexahn snags nanotech platform for cancer drug delivery. Article | Follow @MichaelGFierce

> CalTech team combines two breast cancer drugs using nanoparticles. Report

> Math models tailor drug delivery using patient DNA. Story

> Melbourne team concocts self-assembling, nanoengineered drug delivery tech. Article

> York students eye crowdfunding for nanoparticle cancer patch treatment work. Item

> Oramed raising $4.6M for oral insulin trial. News

And Finally... Studies find that a predicted decline in dementia rates, because of education and health improvements, has proven true. Report

Suggested Articles

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.